KCM
NRIX icon

Kennedy Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Kennedy Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.7M Buy
561,250
+300,046
+115% +$4.98M 0.18% 188
2025
Q4 		$4.96M Buy
261,204
+14,461
+6% +$208K 0.1% 298
2025
Q3 		$2.28M Sell
246,743
-11,073
-4% -$115K 0.05% 431
2025
Q2 		$2.94M Buy
257,816
+52,716
+26% +$570K 0.07% 379
2025
Q1 		$2.44M Buy
205,100
+90,477
+79% +$1.51M 0.06% 407
2024
Q4 		$2.16M Buy
114,623
+785
+0.7% +$18K 0.05% 499
2024
Q3 		$2.56M Buy
113,838
+53,985
+90% +$1.22M 0.06% 469
2024
Q2 		$1.25M Sell
59,853
-28,407
-32% -$442K 0.03% 569
2024
Q1 		$1.3M Sell
88,260
-72,751
-45% -$782K 0.03% 596
2023
Q4 		$1.66M Sell
161,011
-2,612
-2% -$17.9K 0.04% 522
2023
Q3 		$1.29M Buy
163,623
+107,719
+193% +$984K 0.03% 541
2023
Q2 		$558K Buy
+55,904
New +$570K 0.01% 599

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Kennedy Capital Management's NRIX Position: Q1 2026 in Review

Kennedy Capital Management increased its Nurix Therapeutics (NRIX) stake by 115% in Q1 2026, buying an estimated $4.98M and bringing the position to 561,250 shares worth $8.7M. The position accounts for 0.18% of the portfolio, ranked #188.

Kennedy Capital Management first reported a position in NRIX in Q2 2023 and has held it in 12 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Kennedy Capital Management held 561,250 shares of Nurix Therapeutics worth $8.7M as of Q1 2026.
  • Kennedy Capital Management bought 300,046 Nurix Therapeutics shares in Q1 2026, an estimated $4.98M.
  • Nurix Therapeutics made up 0.18% of Kennedy Capital Management's portfolio in Q1 2026, its #188 holding.
  • Kennedy Capital Management first reported a position in Nurix Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.